Our specialist consulting team is dedicated to the pharmaceutical and medical product industry.
We all have prior professional experience from pharma, biotech, medical devices, CROs, scientific institutions, or consulting. Click on the profiles below to explore the backgrounds of the senior members of our consulting team:
John has over 30 years of experience in management consulting and creating value with pharmaceutical and medical product companies. He founded Novasecta in 2003 and has built the company by selecting and developing top quality consultants who work successfully with clients across R&D, corporate/business development and commercial disciplines. John has directed many strategic and management initiatives, achieving amongst others, strategic organisational change, major licensing deals, corporate transformation, optimised asset portfolios, and improvements in strategic partnerships.
Prior to founding Novasecta, John held senior positions in three global consulting firms. He was Head of European Operations at Integral Inc. (now Analysis Group), Director at Strategic Decisions Group (SDG) and Principal at Deloitte Haskins & Sells (now IBM/PWC). John has also raised funds for and developed start-up companies commercially, and has been an executive board member of an intracellular drug delivery spin-out from the University of Cambridge and a novel CNS screening technology start-up company.
John holds an MBA from London Business School, and an MA in Engineering, Economics and Management from Brasenose College, Oxford University.
Tony is a Partner with Novasecta and has almost 30 years of experience in senior executive and non-executive roles in the pharmaceutical and medical product industry. At Novasecta, Tony has primarily been involved in R&D performance improvement, transformation, and business development.
Tony initially worked in senior management roles at Roche for 16 years including Global Head of Clinical Operations for almost 8 years. Since 2002, he has held several executive and non-executive roles in biotech companies in Europe. As CEO, he led successful trade sales of two companies: Cambridge Biotechnology, a pain, inflammation and metabolic diseases company for £25 million and DanioLabs, a neurology and opthalmology company for £15 million. Tony also raised £17.5 million for Novacta Biosystems and £5.2 million for Silence Therapeutics. He has also been an Advisor at Blueberry Therapeutics, a drug discovery company with a nanopolymer discovery platform and at Scottish Enterprise, an economic and policy organisation supporting Scottish businesses.
Tony holds a PhD FRCPath in Pathology/Experimental Pathology from St. Bartholomew’s Hospital Medical School in London.
Chris has over 23 years of management consulting experience. He joined Novasecta as an Associate Partner having previously held a senior management team position in IMS Consulting Group. During his time at IMS, Chris led the Product and Portfolio Strategy Practice in EMEA and led an internal change programme to restructure the organisation of IMS’s global consulting business.
Chris also co-founded and was COO of a consulting firm that focused on the strategic use of sponsorship for clients spanning multiple market sectors including FMCG, telecoms, technology, financial services and consumer electronics. Earlier in his career, Chris was a Senior Associate at Strategic Decisions Group (SDG) where, in addition to his time at IMS Consulting Group, much of his client experience focused on the life sciences sector. Chris has led strategic projects in life cycle management, R&D, devices and market entry across multiple developed and emerging international markets.
Chris has a BSc in Management Science at what is now part of the Manchester Business School and has been tutored in Executive Leadership at IMD in Lausanne.
Brian leads a broad range of engagements with Novasecta clients in the pharmaceutical and medical products industries. He has worked primarily in business unit strategy, product launch strategy, generic drug strategy, pipeline valuation, and partnership search.
Prior to Novasecta, Brian held a variety of finance and commercial positions with GlaxoSmithKline, and started his career as a strategy consultant with the Monitor Group (now Monitor Deloitte).
Brian holds a PhD in Cell and Organism Engineering, and an MA in Natural Sciences, both from the University of Cambridge.
Ed leads a broad selection of engagements at Novasecta, but with a particular focus on commercial improvement in the pharmaceutical industry.
Prior to joining Novasecta, Ed worked for almost 15 years in the pharmaceutical industry for both Merck and GSK, holding a variety of senior marketing positions at country and global level. His experience includes multiple product launches at country and global level, portfolio management and mature product optimisation.
Ed holds an MA in Biological Sciences from Oxford University. In addition he holds a lean Six Sigma Black Belt and is PRINCE2 project management trained.
Mark has experience in R&D and licensing. At Novasecta, Mark has assessed assets and capabilities for R&D organisation and transformation, evaluated companies and strategic fit for in/out licensing, and conducted product and pipeline reviews across multiple therapy areas.
Mark conducted his postgraduate research at the Babraham Institute at the University of Cambridge, studying regulation of cells’ internal signalling. He also worked in multiple editor roles for overseas academic researchers in publications for scientific journals.
Mark holds a PhD in Cellular Signalling from University of Cambridge, and an MSc and BSc in Biochemistry from University of Waikato, New Zealand.
Our Partners and Engagement Managers are supported by a strong group of Associates and Senior Associates to ensure the right balance of skills and experience are applied in each of the consulting teams that works with our clients.